Literature DB >> 30147131

Zoster Vaccine Recombinant, Adjuvanted.

Kalvin Stoker1, Terri L Levien1, Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities:  

Year:  2018        PMID： 30147131      PMCID： PMC6102791          DOI： 10.1177/0018578718767103

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  9 in total

1.  Presentation and management of herpes zoster (shingles) in the geriatric population.

Authors:  Kenneth R Cohen; Rebecca L Salbu; Jerry Frank; Igor Israel
Journal:  P T       Date:  2013-04

2.  Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.

Authors:  Himal Lal; Airi Poder; Laura Campora; Brecht Geeraerts; Lidia Oostvogels; Carline Vanden Abeele; Thomas C Heineman
Journal:  Vaccine       Date:  2017-11-22       Impact factor: 3.641

3.  Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.

Authors:  Roman Chlibek; Karlis Pauksens; Lars Rombo; Gini van Rijckevorsel; Jan H Richardus; Georg Plassmann; Tino F Schwarz; Grégory Catteau; Himal Lal; Thomas C Heineman
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

4.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Authors:  Himal Lal; Anthony L Cunningham; Olivier Godeaux; Roman Chlibek; Javier Diez-Domingo; Shinn-Jang Hwang; Myron J Levin; Janet E McElhaney; Airi Poder; Joan Puig-Barberà; Timo Vesikari; Daisuke Watanabe; Lily Weckx; Toufik Zahaf; Thomas C Heineman
Journal:  N Engl J Med       Date:  2015-04-28       Impact factor: 91.245

5.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

6.  Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Authors:  Elchonon M Berkowitz; Graeme Moyle; Hans-Jürgen Stellbrink; Dirk Schürmann; Stephen Kegg; Matthias Stoll; Mohamed El Idrissi; Lidia Oostvogels; Thomas C Heineman
Journal:  J Infect Dis       Date:  2014-11-03       Impact factor: 5.226

7.  Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.

Authors:  Olivier Godeaux; Martina Kovac; Daniel Shu; Katrijn Grupping; Laura Campora; Martine Douha; Thomas C Heineman; Himal Lal
Journal:  Hum Vaccin Immunother       Date:  2017-01-09       Impact factor: 3.452

8.  Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.

Authors:  Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-26       Impact factor: 17.586

9.  Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.

Authors:  Tino F Schwarz; Naresh Aggarwal; Beate Moeckesch; Isabelle Schenkenberger; Carine Claeys; Martine Douha; Olivier Godeaux; Katrijn Grupping; Thomas C Heineman; Marta Lopez Fauqued; Lidia Oostvogels; Peter Van den Steen; Himal Lal
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226
  9 in total
  1 in total

1.  Small Molecule Calcium Channel Activator Potentiates Adjuvant Activity.

Authors:  Tetsuya Saito; Nikunj M Shukla; Fumi Sato-Kaneko; Yukiya Sako; Tadashi Hosoya; Shiyin Yao; Fitzgerald S Lao; Karen Messer; Minya Pu; Michael Chan; Paul J Chu; Howard B Cottam; Tomoko Hayashi; Dennis A Carson; Maripat Corr
Journal:  ACS Chem Biol       Date:  2022-01-05       Impact factor: 5.100
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.